Clinical trials: sponsored by ECOG-ACRIN Cancer Research Group
Anal Cancer
Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them.
- Trial name
- NCT00316888
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 125 sites in United States
- Volunteers
- 63 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
This randomized phase I/II trial studies the side effects and best dose of fibroblast growth factor receptor (FGFR) inhibitor AZD4547 when given with docetaxel and to see how well it works in treating patients with recurrent…
- Trial name
- NCT01824901
- Testing
- docetaxel, AZD4547
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lymphoma
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01216683
- Testing
- rituximab, Bendamustin, bortezomib
- Where
- 227 sites in United States
- Volunteers
- 289 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer, Stage IV Breast Cancer
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight cancer by blocking the use of estrogen by tumor cells.
- Trial name
- NCT01124695
- Testing
- tamoxifen
- Where
- 294 sites in United States, Canada and 1 more
- Volunteers
- 124 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Malignant Melanoma, Melanoma
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00104884
- Testing
- Depsipeptide
- Volunteers
- 4 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Chronic Lymphocytic Leukemia
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT01013961
- Testing
- alemtuzumab, rituximab
- Where
- 102 sites in United States
- Volunteers
- 31 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Head and Neck Squamous Cell Carcinoma
Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence
This randomized phase II trial studies how well giving afatinib after chemoradiation and surgery works in treating patients with stage III-IV squamous cell carcinoma of the head and neck at high-risk of recurrence.
- Trial name
- NCT01824823
- Testing
- afatinib
- Where
- 272 sites in United States
- Volunteers
- 3 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Colorectal Cancer
Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00002525
- Testing
- fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 859 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma
Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer
This randomized phase II trial studies how well cisplatin and fluorouracil work compared with carboplatin and paclitaxel in treating patients with anal cancer that cannot be removed by surgery, has come back at or near the same…
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma
- Trial name
- InterAACT (NCT02560298)
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Head and Neck Cancer
Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck
RATIONALE: Diagnostic procedures, such as analysis of tumor tissue and lymph nodes that have been surgically removed, may improve the treatment of patients with cancers of the head and neck.
- Trial name
- NCT00002695
- Testing
- DNA stability analysis, microsatellite instability analysis, mutation analysis
- Where
- 4 sites in United States
- Volunteers
- 530 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Kidney Cancer
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01164228
- Testing
- Gemcitabine, Sunitinib
- Where
- 99 sites in United States
- Volunteers
- 87 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
This partially randomized phase I/II trial studies the side effects and best dose of c-Met inhibitor AMG 337 when given together with oxaliplatin, leucovorin calcium, and fluorouracil and to see how well they work in treating…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer
- Trial name
- NCT02344810
- Testing
- c-Met inhibitor AMG 337, oxaliplatin, leucovorin calcium
- Where
- United States
- Sponsor
- Eastern Cooperative Oncology Group
Stage IIIA Non-Small Cell Lung Cancer
Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) works in predicting response to chemotherapy in patients with stage IIIA non-small cell lung cancer…
- Trial name
- NCT02607423
- Testing
- Cisplatin, Computed Tomography, Docetaxel
- Where
- United States
- Sponsor
- ECOG-ACRIN Cancer Research Group
Leukemia
DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897936
- Testing
- DNA methylation analysis, comparative genomic hybridization, fluorescence in situ hybridization
- Volunteers
- 418 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Esophageal Cancer
Genes in Predicting Outcome in Patients With Esophageal Cancer Treated With Cisplatin, Radiation Therapy, and Surgery
RATIONALE: Studying samples of tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898495
- Testing
- loss of heterozygosity analysis, polymerase chain reaction, polymorphism analysis
- Volunteers
- 118 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lymphoma
Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients respond to treatment.
- Trial name
- NCT00898963
- Testing
- gene expression analysis, microarray analysis, polymorphism analysis
- Volunteers
- 175 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Leukemia
DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899366
- Testing
- microarray analysis, mutation analysis, immunologic technique
- Volunteers
- 49 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Colorectal Cancer
Studying DNA and Outcome in Patients With Advanced Colorectal Cancer Treated With Fluorouracil and Oxaliplatin With or Without Bevacizumab on Clinial Trial E-3200
RATIONALE: Studying samples of blood, urine, and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897819
- Testing
- DNA methylation analysis, loss of heterozygosity analysis, microsatellite instability analysis
- Volunteers
- 350 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Leukemia
Studying Tissue Samples to Learn More About Drug Resistance in Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients.
- Trial name
- NCT00900380
- Testing
- flow cytometry, immunological diagnostic method, laboratory biomarker analysis
- Volunteers
- 40 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Melanoma (Skin)
Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer and predict how patients will respond to treatment.
- Trial name
- NCT00897520
- Testing
- recombinant interferon alfa, proteomic profiling, immunoenzyme technique
- Volunteers
- 40 people
- Sponsor
- ECOG-ACRIN Cancer Research Group